DAIAMED

DaiaMed is a clinical-stage biotechnology company focused on the development of oral formulations for peptides and proteins, primarily targeting metabolic diseases. The company leverages a proprietary oral delivery platform designed to protect sensitive molecules from degradation in the gastrointestinal tract and facilitate their absorption into the bloodstream. Its lead program, DM-101, is an oral GLP-1 receptor agonist aimed at treating Type 2 diabetes and obesity by providing a non-invasive alternative to traditional injections. DaiaMed's leadership includes prominent experts in endocrinology and pharmaceutical development, positioning the company to address significant unmet needs in the metabolic health space.